Published Thu, 09 Feb 2017 14:15:58 -0500 on Seeking Alpha
Pfizer Inc. (NYSE: PFE) is one of the world's largest pharmaceutical firms with sales exceeding $50 billion. The company is currently attractively valued at a blended P/E ratio of 13.3, offering a current dividend yield of 4%. Pfizer is awarded an S&P credit rating of AA and possesses a modest debt to capital ratio of 28%.
Prior to 2004, the company could have been described as a fast-growing dividend paying stock. However, since 2004, operating earnings growth has slowed considerably. Therefore, Pfizer was once a powerful total return producer that has morphed into a high-yielding blue-chip dividend paying stock offering only moderate growth potential and an above-average current yield.
Consequently, I believe that Pfizer is best suited for the prudent income-oriented investor seeking above-average current yield and safety. Therefore, Pfizer might be especially interesting to the retired investor looking for an above-average level of income in order to fund their retirement needs. However, I also intend to demonstrate that capital appreciation potential might also be surprisingly good going forward.
Pfizer It's All About The Dividend
I recently read an excellent article titled "Pfizer May Be Another IBM" that DoctoRx authored on Pfizer, and thought it was an excellent piece of research on the company. However, there were certain areas of the article that I did not agree with. To be clear, I found that the article contained... Read more
|Stock name||Last trade||P/E||Earnings/Share||Dividend/Share||Dividend yield|
Older articles featuring Pfizer (PFE):Dividend Income Update: September 2017
My Dividend Growth Portfolio - Q3 2017 Summary
Pfizer: Improving Dividend Prospects
My 86 Stock Portfolio Review- Q3 Dividends UP 16.8% From 2016
Bert's September Dividend Income Summary
More Proof Pfizer's Dividend Is The Only Reason To Own It
Lanny's September Dividend Income Summary
Better Healthcare Dividend Stock: Pfizer Or Novartis?
'Safer' Dividend Dow Dogs Go After Apple, Disney, And IBM Gains Per Broker September Estimates
Sell These 3 Overloved Dividend Stocks Now